Chardan Capital Has Negative Outlook of XENE FY2025 Earnings

Key Points

• Chardan Capital has reduced its FY2025 earnings per share estimate for Xenon Pharmaceuticals to ($4.30), predicting lower performance compared to their previous estimate of ($4.15).
• The stock currently has a "Moderate Buy" consensus rating, with a price target averaging $53.20 following various ratings from analysts.
• Xenon Pharmaceuticals' shares have experienced fluctuations, with a market cap of $2.95 billion and a reported quarterly EPS loss of ($1.07), missing estimates by ($0.04).

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Chardan Capital dropped their FY2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 13th. Chardan Capital analyst R. Li now forecasts that the biopharmaceutical company will post earnings of ($4.30) per share for the year, down from their prior estimate of ($4.15). Chardan Capital currently has a "Buy" rating and a $55.00 target price on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Chardan Capital also issued estimates for Xenon Pharmaceuticals' FY2026 earnings at ($2.15) EPS.

Several other analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Evercore ISI started coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They set an "outperform" rating and a $55.00 target price on the stock. Wedbush boosted their target price on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Tuesday, August 12th. Needham & Company LLC dropped their price target on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Finally, Royal Bank Of Canada dropped their price target on shares of Xenon Pharmaceuticals from $57.00 to $55.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 12th. Eleven research analysts have rated the stock with a Buy rating, According to MarketBeat, Xenon Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $53.20.

Xenon Pharmaceuticals Trading Up 0.7%

NASDAQ:XENE traded up $0.26 during trading hours on Monday, hitting $37.90. 329,653 shares of the stock traded hands, compared to its average volume of 893,331. The firm has a 50 day moving average price of $32.93 and a 200 day moving average price of $34.01. Xenon Pharmaceuticals has a fifty-two week low of $26.74 and a fifty-two week high of $46.00. The firm has a market cap of $2.92 billion, a price-to-earnings ratio of -10.69 and a beta of 1.16.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same period in the prior year, the company earned ($0.75) earnings per share.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC bought a new stake in Xenon Pharmaceuticals during the second quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Xenon Pharmaceuticals during the first quarter valued at about $30,000. Elevation Point Wealth Partners LLC bought a new stake in Xenon Pharmaceuticals during the second quarter valued at about $32,000. L1 Capital Pty Ltd bought a new stake in Xenon Pharmaceuticals during the second quarter valued at about $41,000. Finally, GF Fund Management CO. LTD. bought a new stake in Xenon Pharmaceuticals during the fourth quarter valued at about $63,000. 95.45% of the stock is owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.